Gyre Therapeutics, Inc.GYRENASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+4.2%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

3Y CAGR
+4.2%/yr
Annual compound
Percentile
P93
Near historical high
vs 3Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025127.74%
2024-114.06%
2023142.50%
2022112.75%
2021-52.15%
2020-26.22%
2019-52.74%
2018-43.19%
2017-7.95%
20163.38%